Drug makers get double dose of bad news

Share this article:
Pfizer received non-approvable letters from the FDA regarding Oporia (lasofoxifene), a selective estrogen receptor modulator for the prevention of osteoporosis, and Dynastat (parecoxib sodium), an injectible form of its Cox-2 Bextra.
The company characterized the decisions as having come with little warning.
"These nonapprovals are popping up with no dialogue beforehand to respond to," Pfizer chief medical officer Josph Feczko told The Wall Street Journal.
Pfizer has also submitted Oporia for treating vaginal atrophy in December, but the agency has not responded to that application, a spokeswoman told MM&M.
FDA medical reviewers voted unanimously not to approve Abbott Laboratories' Xinlay (atrasentan), which the company sought to market for treating men with metastatic hormone-refractory prostate cancer.
Members of the Oncologic Drugs Advisory Committee said Abbott's NDA failed to prove that the drug delayed disease progression in the treatment group.
The agency has until October to decide whether to approve it.
Despite the panel's efficacy questions, Abbott said it will continue studying the drug, saying it was encouraged by committee member statements regarding its biological activity. A Phase III trial in hormone-refractory prostate cancer patients without metastasis is ongoing and is scheduled for completion next year.
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...